|
Trial denomination | Objective | Endpoint | ClinicalTrials.gov Identifier |
|
Indapamide versus hydrochlorothiazide in elderly hypertensive patients with renal insufficiency | Evaluate the effects of indapamide SR 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with mild-to-moderate renal insufficiency and hypertension. | Primary outcome measures: renal function Secondary outcome measures: endothelial function, blood pressure variability | NCT01172431 |
|
Compare the effects of Lercanidipine Hydrochloride Tablet (Zanidip) and Felodipine sustained-release tablet for Hypertension | Compare felodipine sustained-release tablets to Lercanidipine hydrochloride tablets (Zanidip ) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on patients’ heart rate and blood pressure variability. | Primary outcome measures: change from baseline in mean seated diastolic BP in clinical after 6 weeks of treatment Change from baseline in mean seated systolic BP after 6 weeks of treatment | NCT01520285 |
|
ARB and CCB longest combination treatment on ambulatory and home BP in hypertension with atrial fibrillation-multicenter study on time of Dosing (ACROBAT) | Evaluate of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting ARB-CCB tablet between morning administration and bedtime administration. | Primary outcome measures: change in 24-hour average BP from baseline to week 12. Secondary outcome measures: Change in BP at nighttime, early-morning, and daytime from baseline to Week 12. Change in BPV from baseline to Week 12. | NCT01748253 |
|
Renal sympathetic modification in patients with metabolic syndrome | Assess the incident of composite cardiovascular events after renal sympathetic modification using THERMOCOOL catheter in patients with metabolic syndrome, and evaluate safety and efficacy of the intervention. | Primary outcome measures: composite cardiovascular events (myocardial infarction, heart failure, sudden death, cardiogenic death) Secondary outcome measures: effect on glucose and lipid metabolism and BPV | |
|
Comparison of bisoprolol with metoprolol succinate sustained-release on heart rate and blood pressure in hypertensive patients (CREATIVE) | Demonstrate the superiority and/or noninferiority of bisoprolol on metoprolol succinate sustained-release (SR) | Primary outcome measures: change of mean diastolic ABPM in the last 4 hours after 12-week treatment from baseline. Secondary outcome measures: change of mean ambulatory 24 h, daytime and nighttime BP 24-hour variability of BP | NCT01508325 |
|